ClinicalTrials.gg
Active, not recruitingNCT03922724Updated Nov 19, 2026

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

A Phase 2 interventional study of ATL-RIC and mRIC in Peripheral T-cell Lymphomas, Lymphoproliferative Disorders and Immune System Diseases, sponsored by National Cancer Institute (NCI). Active, not recruiting at 2 sites in United States. Open to participants aged 12 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

Updated Oct 20, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Non-randomized
Ages
12 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Lymphoma, T-Cell, Peripheral by National Cancer Institute (NCI) — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma, T-Cell, Peripheral · National Cancer Institute (NCI).

Enrollment
2nd of 15
118 · median 36
Started
2019
the only one that year
Phase 2
4 of 16
none open now
Registered
13th of 16
by date

Among the 16 studies in Lymphoma, T-Cell, Peripheral by National Cancer Institute (NCI), this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 2, and was the 13th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

1 of the 16 studies in Lymphoma, T-Cell, Peripheral by National Cancer Institute (NCI) is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 12 Years to 120 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Lymphoma, T-Cell, Peripheral by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause.

Objective:

To test if a stem cell transplant can cure or control lymphoma. Also to test if new ways of getting a recipient ready for a transplant may result in fewer problems and side effects.

Eligibility:

Recipients: People ages 12 and older with peripheral T cell lymphoma that does not respond to standard treatments

Donors: Healthy people ages 18 and older whose relative has lymphoma

Design:

Participants will be screened with:

Physical exam

Blood and urine tests

Bone marrow biopsy: A needle inserted into the participant s hip bone will remove marrow.

Donors will also be screened with:

X-rays

Recipients will also be screened with:

Lying in scanners that take pictures of the body

Tumor sample

Donors may donate blood. They will take daily shots for 5 7 days. They will have apheresis: A machine will take blood from one arm and take out their stem cells. The blood will be returned into the other arm.

Recipients will be hospitalized at least 2 weeks before transplant. They will get a catheter: A plastic tube will be inserted into a vein in the neck or upper chest. They will get antibody therapy or chemotherapy.

Recipients will get the transplant through their catheter.

Recipients will stay in the hospital several weeks after transplant. They will get blood transfusions. They will take drugs including chemotherapy for about 2 months.

Recipients will have visits 6, 12, 18, 24 months after transplant, then once a year for 5 years.

Read the detailed description

Background:

  • Mature neoplasms of T and/or natural killer cells, collectively called peripheral T-cell lymphomas (PTCL), are often poorly responsive to chemotherapy and therefore associated with significant morbidity and mortality.
  • Allogeneic hematopoietic cell transplantation (HCT) has the potential to cure PTCL but the optimal approach to HCT for these diseases requires ongoing investigation

Objectives:

  • For subjects on the reduced-intensity conditioning (RIC/mRIC) arms, to estimate the progression-free survival
  • For subjects on the immunosuppression-only conditioning (IOC) and ATL/RIC arms, because they are high risk patients, to preliminarily estimate the proportion who are progression free at one year.

Eligibility:

  • Patients age >= 12 years
  • PTCL that is relapsed or refractory to prior therapy and/or PTCL of a risk score where upfront allo HCT in first remission is reasonable (PIT score of intermediate-low risk or higher or supported by clinical practice guidelines1)
  • At least one potentially suitable 7-8/8 HLA-matched related or unrelated donor (at HLA A, B, C, and DR), or an HLA-haploidentical related donor
  • Adequate end-organ function
  • Not pregnant or breastfeeding

Design:

  • There will be four recipient treatment arms that vary in approach, although all with the same backbone of conditioning and GVHD prophylaxis:

    • Immunosuppression-only conditioning (IOC) arm for high-risk subjects
    • Reduced-intensity conditioning (RIC) arm for those deemed not high-risk and able to tolerate RIC and without adult T cell leukemia/lymphoma (ATL)
    • mRIC arm for patients eligible for the RIC arm, as a modified expansion upon completion of the RIC arm
    • ATL-RIC arm for patients with a diagnosis of ATL
  • IOC arm: equine anti-thymocyte globulin (e-ATG) 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -9 and -5, low-dose cyclophosphamide (5 mg/kg) orally daily on days -9 through -2

    --Subjects will be assigned to the IOC arm if there is significant end-organ dysfunction present and it is felt that a conditioning regimen that includes busulfan would likely be associated with intolerable or life-threatening toxicities for the patient. Patients will also be assigned to the IOC arm if they possess a DNA repair defect, telomere maintenance defect, or familial cancer predisposition syndrome that necessitates limiting chemotherapy as much as possible to prevent future cancer risk.

  • RIC arm: e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through - 4; busulfan IV, pharmacokinetically dosed, on days -3 and -2.
  • mRIC arm: e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through - 4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5 mcg/kg/day subcutaneous on days -12, -8, and -4.
  • ATL-RIC arm: e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5 mcg/kg/day subcutaneous on days -12, -8, and -4, ruxolitinib 45 mg/day from day -12 through day -2, and zidovudine 300 mg orally three times a day from day -1 through day +50.
  • Peripheral blood stem cells are the preferred graft source, although bone marrow is permitted
  • GVHD prophylaxis: Post-transplantation cyclophosphamide (PTCy) on days +3 and +4 (50 mg/kg/day on RIC arm, mRIC, and ATL-RIC arms and 25 mg/kg/day on the IOC arm, with the option of 25 mg/kg/day on the RIC arm). Sirolimus on days +5 through +60 (RIC arm, mRIC arm, IOC arm). Patients with somatic mutations in the Akt/mTOR pathway may receive tacrolimus days +5 through +60 instead of sirolimus on the RIC, mRIC, or IOC arms. Mycophenolate mofetil (MMF) on days +5 through +25 on the RIC, IOC, and mRIC arms; MMF will not be given on the ATL-RIC arm. Patients on the ATL-RIC arm will receive tacrolimus on days +5 through +50 and ruxolitinib 15 mg/day from days +5 through +35, 10 mg/day from days +36 through +60, and 5 mg/day from days +61 through +70.
03

Conditions studied

  • Peripheral T-cell Lymphomas
  • Lymphoproliferative Disorders
  • Immune System Diseases

Keywords

  • Autoimmunity
  • Immune Dysregulation
  • Congenital
  • Opportunistic Infection
04

Who can participate

Ages eligible
12 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • INCLUSION CRITERIA-RECIPIENT:
  • Age >=12 years
  • Diagnosis of PTCL, confirmed by NCI pathology review, that is to prior therapy, and/or PTCL where upfront allo HCT in first remission is reasonable (PIT score of intermediate-low risk or higher or supported by clinical practice guidelines)

    --ALK-positive ALCL patients will only be eligible if relapsed or refractory

  • At least one potential 7-8/8 HLA-matched related (excluding an identical twin) or unrelated donor (at HLA-A, -B, -C, and DR), or an HLA-haploidentical related donor, based on initial low resolution unrelated donor search and/or at least one biologically-related family member who has at least a 25% chance of being at minimum an HLAhaploidentical match and is potentially suitable to donate based on reported family history. HLA typing of potential donors and/or mutation testing does not need to be completed for eligibility.
  • Adequate end-organ function, as measured by:

    • For RIC: (LVEF) >= 40% by 2D echocardiogram (ECHO) or MUGA, left ventricular shortening fraction >= 20% by ECHO, or LVEF >= 30% if the patient has radiologic evidence of aortic, renal, or coronary artery vasculitis. For IOC: LVEF >= 30% by 2D ECHO or MUGA.
    • Pulmonary function tests: DLco (corrected for ) and >= 40% of predicted for the RIC arm, and >= 30% predicted for the IOC arm; or in pediatric patients, if unable to perform pulmonary function tests, there should be no evidence of dyspnea at rest, no requirement for supplemental oxygen, and oxygen saturation >92% on room air.
    • \<= 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis) for patients receiving RIC and bilirubin \<= 5.0 mg/dL for patients receiving IOC (unless due to Gilbert s syndrome or hemolysis); and AST \<= 10 x for patients receiving RIC or IOC. Patients who are above these bilirubin, ALT, or AST thresholds may be eligible for the RIC or IOC arm if evaluated by a hepatologist who deems the liver function test abnormalities to be potentially disease related, either because of direct involvement by PTCL, due to an associated process such as hemophagocytic lymphohistiocytosis, or as sequelae of prior chemotherapy that is thought to improve with time.
    • Estimated of >= 50 mL/min/1.73 m\^2, calculated using in the clinical lab for adults and the Schwartz formula for pediatrics.
  • (adults) or Lansky (children) performance status of >= 50% or performance status of 2 or less for the RIC arm and Karnofsky (adults) or Lansky (children) >= 30% or ECOG performance status of 3 or less for the IOC arm
  • Ability of subject or parent/guardian to understand and the willingness to sign a written document
  • Not pregnant or breastfeeding.
  • As therapeutic agents used in this trial may be harmful to a fetus, individuals of and individuals who can father children must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least one year post-allo HCT.

EXCLUSION CRITERIA-RECIPIENT:

  • Patients who are receiving any other agents, with the exception of virus-specific cytotoxic T-cells for the treatment of viral infection/reactivation prior to allo HCT.
  • Prohibitive allergy to a study drug or to compounds of similar chemical or biologic composition of the agents (e-ATG, , cyclophosphamide, busulfan, pentostatin, sirolimus, MMF, filgrastim or biosimilar drug) used in the study
  • Lack of central venous access potential
  • Active psychiatric disorder which is deemed by the PI to have significant risk of compromising compliance with the transplant protocol or which does not allow for appropriate informed consent

INCLUSION CRITERIA-RELATED DONOR:

-Related donor deemed suitable and eligible, and willing to donate, per clinical evaluations who are additionally willing to donate blood and/or peripheral blood stem cells for research. Related donors will be evaluated in accordance with existing Standard Policies and Procedures for determination of eligibility and suitability for clinical donation.

EXCLUSION CRITERIA-RELATED DONOR:

None

INCLUSION CRITERIA (UNRELATED DONOR):

-Unrelated donors will be evaluated in accordance with existing NMDP Standard Policies and Procedures, available at: http://bethematch.org/About-Us/Global-transplantnetwork/ Standards/, except for the additional requirement of EBV serostatus testing for clinical purposes of donor selection. Note that participation in this study is offered to all unrelated donors but not required for clinical donation, so it is possible that not all unrelated donors will enroll on this study. Unrelated donors only enroll if they contribute research specimens, which is optional.

EXCLUSION CRITERIA (UNRELATED DONOR):

-Unrelated donors: failure to qualify as a National Marrow Donor Program (NMDP) donor per current NMDP Standards, available at: http://bethematch.org/About-Us/Globaltransplant- network/Standards/. Exceptions to donor eligibility (e.g. foreign travel, tattoos) do not automatically exclude the donor and will be reviewed by the PI.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    1/RIC Arm

    Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis

    Procedure: allo HCT · Drug: RIC · Drug: GVHD prophylaxis

  • Experimental
    2/IOC Arm

    Immunosuppression Only Conditioning, plus allogeneic HCT with GVHD prophylaxis

    Procedure: allo HCT · Drug: GVHD prophylaxis · Drug: IOC

  • No intervention
    3/Donor Arm

    Donors for Recipients in Arm 1, Arm 2, Arm 4, or Arm 5

  • Experimental
    4/mRIC Arm

    modified Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis

    Drug: mRIC · Procedure: allo HCT · Drug: GVHD prophylaxis

  • Experimental
    5/ATL-RIC Arm

    modified Reduced Intensity Conditioning Arm for ATL patients, plus allogeneic HCT with GVHD prophylaxis

    Drug: ATL-RIC · Procedure: allo HCT · Drug: GVHD prophylaxis

Interventions

  • DrugATL-RIC

    e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5mcg /kg/day subcutaneous on days -12, -8, and -4, ruxolitinib 45 mg/day from day -12 through day -2, and zidovudine 300mg orally three times a day from day -1 through day +50.

  • DrugmRIC

    e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, lowdose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5 mcg/kg/day subcutaneous on days -12, -8, and -4.

  • Procedureallo HCT

    Stem cell transplant

  • DrugRIC

    e-ATG 40 mg/kg/day IV on days -14 and -13. Pentostatin 4mg /m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally daily on days -11 through -4. Busulfan IV, pharmacokinetically dosed, on days -3 and -2.

  • DrugGVHD prophylaxis

    High-dose, post-transplantation cyclophosphamide (PTCy) on days +3 and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on days +5 through +25.

  • DrugIOC

    e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) of HCT recipients on the RIC arm and the mRIC arm

    Number of patients who are alive and with PFS at one year, assessed by Kaplan-Meier with 80% and 95% two-sided confidence intervals

    Time frame: 1 year post transplant

  2. Progression-free survival (PFS) of HCT recipients on the IOC arm and ATL-RIC arm

    Number of patients who are alive and with PFS at one year, assessed by Kaplan-Meier with 80% and 95% two-sided confidence intervals

    Time frame: 1 year post transplant

Secondary outcomes

  1. Incidence of Acute Graft versus-host disease

    Cumulative incidence of acute graft versus host disease at 1 year post transplant

    Time frame: 1 year post transplant

  2. Incidence of Chronic Graft versus-host disease

    Cumulative incidence of chronic graft versus host disease at 1 and 2 years post transplant.

    Time frame: 1 and 2 years post transplant

  3. primary graft failure

    Cumulative incidence of secondary graft failure at 60 days post transplant.

    Time frame: 60 days post transplant

  4. secondary graft failure

    Cumulative incidence of secondary graft failure at 1 year post transplant.

    Time frame: 1 year post transplant

  5. lymphoma relapse

    Time from transplant to disease relapse

    Time frame: 1, 3, and 5 years post transplant

  6. transplant-related mortality

    Time from transplant to transplant-related death

    Time frame: 180 days and 1 year post transplant

  7. kinetics and durability of engraftment

    The percentage of donor T-, B-, NK-, and myeloid cell populations

    Time frame: days +28, +42, +60, +100, +180, and 1 year post transplant

  8. kinetics and durability of lineage-specific donor chimerism

    Association between early chimerism data and primary or secondary graft failure

    Time frame: days +21, +28, +35, +42, and + 60 post transplant

  9. disease-free survival

    Time from transplant to death of any cause or disease relapse.

    Time frame: 1, 3, and 5 years post transplant

  10. event-free survival

    Time from transplant to death of any cause or other event, including disease relapse, graft failure

    Time frame: 1, 3, and 5 years post transplant

  11. overall survival

    Time from transplant to death of any cause

    Time frame: 1, 3, and 5 years post transplant

  12. incidence of EBV, CMV, JCV, BKV, adenovirus, and HHV6

    cumulative incidence of EBV, CMV, JCV, BKV, adenovirus, and HHV6 in blood

    Time frame: day +100 post transplant

  13. GVHD-free graft failure-free survival (GGFS)

    Time from transplant to primary or secondary graft failure and death due to grade 3-4 acute GVHD not responsive to seven days of high dose steroids

    Time frame: 1, 3, and 5 years post transplant

  14. GVHD-free relapse-free survival (GRFS)

    Time from transplant to death from any cause of other event

    Time frame: 1, 3, and 5 years post transplant

07

Study locations

2 sites
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
  • National Marrow Donor Program
    Minneapolis, Minnesota 55401, United States
08

References and documents

Individual participant data

Plan to share: Yes — All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGAP.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as the database is active.

Access criteria: Clinical data will be made available via subscription to BTRIS and with permission of the study PI. Genomic data are made available via dbGAP through requests to the data custodians

09

Timeline

7 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Jun 2027, 97 months after the start.

Of 44 non-industry phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 110. This study's planned 97 months is above that.

Counting every sponsor, half of 64 studies reached it within 61 months; a quarter within 38 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2019
First posted
Apr 22, 2019
StartActual
Apr 18, 2019
Primary completionEst.
Jun 1, 2027
CompletionEst.
Oct 31, 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
91→118
Oct 20, 2026
Show all 7 updates
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: verification date
  2. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  3. Nov 2, 2026
    Minor edits only
    + 1 other change: verification date
  4. Oct 22, 2026
    Minor edits only
    + 1 other change: verification date
  5. Oct 21, 2026
    Minor edits only
    + 1 other change: verification date
  6. Oct 20, 2026
    Enrollment 91→118
  7. Oct 16, 2026
    Minor edits only
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03922724
Responsible party
Sponsor
First posted
Apr 22, 2019
Start date
Apr 18, 2019
Primary completion
Jun 1, 2027 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Dimana Dimitrova, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion